Pars Plana Vitrectomy Clinical Trial
Official title:
Evaluation of Pars Plana Vitrectomy With Internal Limiting Membrane Peeling for Myopic Traction Maculopathy
Investigate the effectiveness and safety of pars plans vitrectomy, with internal limiting membrane peeling for cases of myopic traction maculopathy
Performing pars plana vitrectomy for highly myopic patients with decreased visual acuity is the standard of care for patients with myopic traction. A variety of findings are seen by Optical Coherence Tomography. Epiretinal membranes, retinoschisis, lamellar macular holes, and full thickness macular holes are seen. Undergoing vitrectomy, with or without tamponade, in our center, is retrospectively evaluated. Visual acuity change, as well as improvement of the retinal structure by OCT will be examined. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05990829 -
Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed by Intraoperative OCT (the VIDEO Study): Study Protocol for a Randomized Controlled Trial
|
Phase 4 | |
Recruiting |
NCT05631054 -
Establishment and Validation of a Risk Prediction Model for Long-term Low Vision After Vitrectomy in PDR Patients
|
||
Recruiting |
NCT05728476 -
Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema
|
N/A | |
Recruiting |
NCT04774146 -
Quantification of Silicone Oil Emulsification After Pars Plana Vitrectomy
|
||
Not yet recruiting |
NCT05592912 -
Safety and Efficacy of HydroLenz for Vitrectomy-Induced Lens Opacities
|
Phase 1 | |
Completed |
NCT05013281 -
Suprachoroidal Hemorrhage Associated With Pars Plana Vitrectomy
|
||
Completed |
NCT00548197 -
Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment
|
Phase 1 | |
Terminated |
NCT00936520 -
SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy
|
Phase 1 | |
Recruiting |
NCT05248334 -
A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy
|
Phase 1 |